Login to Your Account

Biotie Shares Drop as Roche Passes on 5-HT6 Drug SYN120

By Cormac Sheridan
Staff Writer

Wednesday, August 8, 2012

Shares in Biotie Therapies Oyj dropped nearly 10 percent Tuesday on news that Roche Holding AG decided not to exercise an option on its selective serotonin (5-hydroxytryptamine) receptor subtype 6 (5-HT6) antagonist SYN-120.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription